Download PDF
CC BY-NC-ND 4.0 · AJP Rep 2019; 09(03): e213-e217
DOI: 10.1055/s-0039-1692198
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis

Yuka Shibata
1   Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan
,
Hidehiko Maruyama
1   Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan
,
Taiyu Hayashi
2   Division of Cardiology, National Center for Child Health and Development, Setagaya, Tokyo, Japan
,
Hiroshi Ono
2   Division of Cardiology, National Center for Child Health and Development, Setagaya, Tokyo, Japan
,
Yuka Wada
1   Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan
,
Hideshi Fujinaga
1   Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan
,
Shuhei Fujino
1   Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan
,
Junko Nagasawa
1   Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan
,
Shoichiro Amari
1   Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan
,
Keiko Tsukamoto
1   Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan
,
Yushi Ito
1   Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Setagaya, Tokyo, Japan
› Author Affiliations Funding No financial assistance was received to support this study.
Further Information

Publication History

08 November 2018

05 March 2019

Publication Date:
11 July 2019 (online)

   Permissions and Reprints

Abstract

Most cardiac rhabdomyomas with tuberous sclerosis (TS) are asymptomatic and spontaneously regress. However, some cases require surgical intervention due to arrhythmia and severe obstruction of cardiac inflow or outflow. We report herein a neonatal case of giant cardiac rhabdomyomas with TS and insufficient pulmonary blood flow from the right ventricle. Lipoprostaglandin E1 was necessary to maintain patency of the ductus arteriosus. We used everolimus, a mammalian target of rapamycin inhibitor, to diminish the cardiac rhabdomyomas. After treatment, the rhabdomyomas shrank rapidly, but the serum concentration of everolimus increased sharply (maximum serum trough level: 76.1 ng/mL) and induced complications including pulmonary hemorrhage, liver dysfunction, and acne. After the everolimus level decreased, the complications resolved. Everolimus may be a viable treatment option for rhabdomyomas, but its concentration requires close monitoring to circumvent complications associated with its use.

Keywords

complication - everolimus - rhabdomyoma - tuberous sclerosis

Ethical Approval

All the procedures involving human participants were performed in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments. The approval of the ethics review committee and parental consent to use everolimus were obtained. Parental written informed consent was obtained for this report.


 

  • References

  • 1 Northrup H, Krueger DA. ; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49 (04) 243-254
    CrossrefPubMedGoogle Scholar
  • 2 Chan JA, Zhang H, Roberts PS. , et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004; 63 (12) 1236-1242
    CrossrefPubMedGoogle Scholar
  • 3 Krueger DA, Care MM, Holland K. , et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363 (19) 1801-1811
    CrossrefPubMedGoogle Scholar
  • 4 Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001; 105 (03) 357-368
    CrossrefPubMedGoogle Scholar
  • 5 Smythe JF, Dyck JD, Smallhorn JF, Freedom RM. Natural history of cardiac rhabdomyoma in infancy and childhood. Am J Cardiol 1990; 66 (17) 1247-1249
    CrossrefPubMedGoogle Scholar
  • 6 Franz DN, Belousova E, Sparagana S. , et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381 (9861): 125-132
    CrossrefPubMedGoogle Scholar
  • 7 Bissler JJ, Kingswood JC, Radzikowska E. , et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381 (9869): 817-824
    CrossrefPubMedGoogle Scholar
  • 8 Krueger DA, Wilfong AA, Holland-Bouley K. , et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74 (05) 679-687
    CrossrefPubMedGoogle Scholar
  • 9 Aw F, Goyer I, Raboisson MJ, Boutin C, Major P, Dahdah N. Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis complex. Pediatr Cardiol 2017; 38 (02) 394-400
    CrossrefPubMedGoogle Scholar
  • 10 Doğan V, Yeşil Ş, Kayalı Ş. , et al. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus. J Trop Pediatr 2015; 61 (01) 74-77
    CrossrefPubMedGoogle Scholar
  • 11 Bornaun H, Öztarhan K, Erener-Ercan T. , et al. Regression of cardiac rhabdomyomas in a neonate after everolimus treatment. Case Rep Pediatr 2016; 2016: 8712962
    PubMedGoogle Scholar
  • 12 Goyer I, Dahdah N, Major P. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatr Neurol 2015; 52 (04) 450-453
    CrossrefPubMedGoogle Scholar
  • 13 Shigemitsu Y, Baba K, Kondo M. , et al. Regression of massive cardiac rhabdomyoma causing circulatory collapse with everolimus therapy. Pediatr Cardiol Cardiac Surg 2016; 32: 439-444
    PubMedGoogle Scholar
  • 14 Demir HA, Ekici F, Yazal Erdem A, Emir S, Tunç B. Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma. Pediatrics 2012; 130 (01) e243-e247
    CrossrefPubMedGoogle Scholar
  • 15 Mohamed I, Ethier G, Goyer I, Major P, Dahdah N. Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect. BMJ Case Rep 2014; 2014: pii: bcr2014205138
    PubMedGoogle Scholar
  • 16 Colaneri M, Quarti A, Pozzi M. Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex. Cardiol Young 2016; 26 (05) 1025-1028
    CrossrefPubMedGoogle Scholar
  • 17 Wagner R, Riede FT, Seki H. , et al. Oral everolimus for treatment of a giant left ventricular rhabdomyoma in a neonate-rapid tumor regression documented by real time 3D echocardiography. Echocardiography 2015; 32 (12) 1876-1879
    CrossrefPubMedGoogle Scholar
  • 18 Fujino M, Ehara E, Kuki I. , et al. Rapid regression of cardiac rhabdomyoma after everolimus administration in an infant with tuberous sclerosis. Pediatr Cardiol Cardiac Surg 2016; 32: 251-256
    PubMedGoogle Scholar
  • 19 Stiller B, Hetzer R, Meyer R. , et al. Primary cardiac tumours: when is surgery necessary?. Eur J Cardiothorac Surg 2001; 20 (05) 1002-1006
    CrossrefPubMedGoogle Scholar
  • 20 Bielefeld KJ, Moller JH. Cardiac tumors in infants and children: study of 120 operated patients. Pediatr Cardiol 2013; 34 (01) 125-128
    CrossrefPubMedGoogle Scholar
  • 21 Masuda S. Individualized dosage of everolimus in organ transplant patients by evidence based medicine. Organ Biology 2015; 22: 105-110
    PubMedGoogle Scholar
  • 22 Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 2012; 61 (02) 47-56
    CrossrefPubMedGoogle Scholar
  • 23 Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest 2010; 137 (02) 456-459
    CrossrefPubMedGoogle Scholar
  • 24 Fielhaber JA, Carroll SF, Dydensborg AB. , et al. Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis. J Immunol 2012; 188 (09) 4535-4542
    CrossrefPubMedGoogle Scholar
  • 25 Uesugi M, Kikuchi M, Shinke H. , et al. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. Pharmacogenet Genomics 2014; 24 (07) 356-366
    CrossrefPubMedGoogle Scholar
  • 26 Kotulska K, Chmielewski D, Borkowska J. , et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol 2013; 17 (05) 479-485
    CrossrefPubMedGoogle Scholar